Ticino Wealth Buys New Holdings in Amgen Inc. $AMGN

Ticino Wealth acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,769 shares of the medical research company’s stock, valued at approximately $2,543,000.

Several other institutional investors have also recently made changes to their positions in the business. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter valued at about $26,000. Olistico Wealth LLC purchased a new position in shares of Amgen during the 4th quarter valued at approximately $33,000. Cloud Capital Management LLC acquired a new stake in Amgen during the third quarter valued at $34,000. Saranac Partners Ltd acquired a new position in shares of Amgen in the third quarter worth about $37,000. Finally, Holos Integrated Wealth LLC purchased a new position in shares of Amgen in the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 2.1%

Shares of AMGN stock opened at $342.97 on Tuesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The firm has a market cap of $185.09 billion, a PE ratio of 24.55, a price-to-earnings-growth ratio of 3.71 and a beta of 0.47. The company has a 50-day moving average of $362.40 and a two-hundred day moving average of $338.35. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the business posted $5.31 EPS. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts predict that Amgen Inc. will post 22.18 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s payout ratio is presently 70.84%.

Analysts Set New Price Targets

Several equities research analysts recently commented on AMGN shares. Morgan Stanley boosted their price target on shares of Amgen from $309.00 to $326.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Jefferies Financial Group began coverage on shares of Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price for the company. Royal Bank Of Canada raised their price target on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $356.62.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.